title: Mild cognitive impairment.
abstract: Mild cognitive impairment is a syndrome defined as cognitive decline greater than expected for an individual's age and education level but that does not interfere notably with activities of daily life. Prevalence in population-based epidemiological studies ranges from 3% to 19% in adults older than 65 years. Some people with mild cognitive impairment seem to remain stable or return to normal over time, but more than half progress to dementia within 5 years. Mild cognitive impairment can thus be regarded as a risk state for dementia, and its identification could lead to secondary prevention by controlling risk factors such as systolic hypertension. The amnestic subtype of mild cognitive impairment has a high risk of progression to Alzheimer's disease, and it could constitute a prodromal stage of this disorder. Other definitions and subtypes of mild cognitive impairment need to be studied as potential prodromes of Alzheimer's disease and other types of dementia.
authors.affiliation: McGill Center for Studies in Aging, Douglas Hospital, Montréal, Quebec, Canada. serge.gauthier@mcgill.ca
authors.forename: Serge
authors.initials: S
authors.lastname: Gauthier
authors.forename: Barry
authors.initials: B
authors.lastname: Reisberg
authors.forename: Michael
authors.initials: M
authors.lastname: Zaudig
authors.forename: Ronald C
authors.initials: RC
authors.lastname: Petersen
authors.forename: Karen
authors.initials: K
authors.lastname: Ritchie
authors.forename: Karl
authors.initials: K
authors.lastname: Broich
authors.forename: Sylvie
authors.initials: S
authors.lastname: Belleville
authors.forename: Henry
authors.initials: H
authors.lastname: Brodaty
authors.forename: David
authors.initials: D
authors.lastname: Bennett
authors.forename: Howard
authors.initials: H
authors.lastname: Chertkow
authors.forename: Jeffrey L
authors.initials: JL
authors.lastname: Cummings
authors.forename: Mony
authors.initials: M
authors.lastname: de Leon
authors.forename: Howard
authors.initials: H
authors.lastname: Feldman
authors.forename: Mary
authors.initials: M
authors.lastname: Ganguli
authors.forename: Harald
authors.initials: H
authors.lastname: Hampel
authors.forename: Philip
authors.initials: P
authors.lastname: Scheltens
authors.forename: Mary C
authors.initials: MC
authors.lastname: Tierney
authors.forename: Peter
authors.initials: P
authors.lastname: Whitehouse
authors.forename: Bengt
authors.initials: B
authors.lastname: Winblad
mesh_terms: D000368:Aged; D018680:Cholinergic Antagonists / Q000009:adverse effects; D002986:Clinical Trials as Topic; D003072:Cognition Disorders / Q000145:classification / Q000175:diagnosis / Q000503:physiopathology; D003704:Dementia / Q000209:etiology*; D018450:Disease Progression; D006801:Humans; D008568:Memory; D012720:Severity of Illness Index
chemical_list: D018680:Cholinergic Antagonists